Jonathan Dore, PA
Physician Assistant · Clifton Park, NYNPI 1750887329
Payments from drug & device makers
Across 323 payments — averaging $17.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$823
- Novo Nordisk$724
- Boehringer Ingelheim$488
- AstraZeneca$456
- Amgen$395
- GSK$368
- plus $2K from 32 others
What the payments were for
- Food & beverage$5,698100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 58 | $823 |
| Novo Nordisk | 41 | $724 |
| Boehringer Ingelheim | 23 | $488 |
| AstraZeneca | 25 | $456 |
| Amgen | 22 | $395 |
| GSK | 23 | $368 |
| Abbott | 17 | $320 |
| Lilly USA, LLC | 15 | $295 |
| Pfizer | 17 | $256 |
| Astellas Pharma US Inc | 7 | $150 |
| Biohaven Pharmaceuticals, Inc. | 8 | $142 |
| Phathom Pharmaceuticals, Inc. | 8 | $129 |
| Idorsia Pharmaceuticals US Inc | 5 | $94 |
| Biohaven Pharmaceutical Holding Company Ltd. | 5 | $91 |
| Esperion Therapeutics, Inc. | 4 | $82 |
| Merck | 4 | $70 |
| Otsuka America Pharmaceutical, Inc. | 3 | $64 |
| Seqirus USA Inc | 3 | $63 |
| Johnson & Johnson | 4 | $61 |
| Viatris Specialty LLC | 2 | $48 |
| Axsome Therapeutics, Inc. | 3 | $47 |
| UCB, Inc. | 1 | $46 |
| Exact Sciences | 2 | $45 |
| Lundbeck LLC | 2 | $44 |
| Jazz Pharmaceuticals Inc. | 2 | $43 |
| Sanofi Pasteur Inc. | 2 | $38 |
| Exeltis, USA Inc. | 2 | $36 |
| Amarin Pharma, Inc. | 2 | $35 |
| Gilead | 2 | $34 |
| Amneal Pharmaceuticals LLC | 2 | $30 |
| Dynavax Technologies Corporation | 1 | $29 |
| Sumitomo Pharma America, Inc. | 2 | $26 |
| Eisai Inc. | 1 | $25 |
| Tactile Systems Technology Inc | 1 | $24 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $22 |
| Kowa Pharmaceuticals America, Inc. | 1 | $19 |
| Bayer | 1 | $18 |
| IBSA Pharma Inc. | 1 | $16 |
How this compares
$5,698 in reported general payments places this provider in the 90th percentile of 11,358 physician assistant providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 63 | $71,679 |
| OzempicSemaglutide | 39 | $65,982 |
| EliquisApixaban | 52 | $41,307 |
| FarxigaDapagliflozin Propanediol | 37 | $29,153 |
| RybelsusSemaglutide | 21 | $26,397 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 22 | $15,966 |
| MounjaroTirzepatide | 11 | $11,394 |
| MyrbetriqMirabegron | 17 | $10,755 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 11 | $6,907 |
| Atorvastatin Calcium | 308 | $3,926 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 11 | $3,538 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 27 | $3,442 |
| Rosuvastatin Calcium | 133 | $2,636 |
| Ezetimibe | 52 | $1,878 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 59 | $1,763 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $724 | $92,37960 claims |
| Boehringer IngelheimJardiance | $488 | $71,67963 claims |
| PfizerEliquis | $256 | $41,30752 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $456 | $36,06048 claims |
| GSKTrelegy Ellipta | $368 | $15,96622 claims |
| Lilly USA, LLCMounjaro | $295 | $11,39411 claims |
| Astellas Pharma US IncMyrbetriq | $150 | $10,75517 claims |
| AbbVieSynthroid | $823 | $1,26918 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $30 | $1,25882 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 11,358 physician assistant providers in New York.
Other physician assistant in Clifton Park
- Henry YuBronx$1M
- Michael AsbachAmherst$962K
- Janelle BunceJamestown$565K
- Kristyl Cuenca-SiskoNew York$478K
- Melissa WhiteGarden City$320K
- Lawrence HermanHolbrook$315K
- Kaitlyn NelsonBrooklyn$289K
- Sari KatzGarden City$271K
- Julius NwosuBronx$256K
- Cameron KiserNew York$225K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.